Faculty

Institution

Unit

Venue

Lori Rink

Associate Professor

Drexel University

Affiliations

College of Medicine

Biochemistry & Molecular Biology

Lori Rink is currently serving as a Biochemistry & Molecular Biology Associate Professor at Drexel University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Lori Rink

Drexel University

Associate Professor

You can click a keyword to filter the displayed items

oncology pharmacology cancer research cancer biology tumor biology cell biology gastrointestinal stromal tumors gastrointestinal stromal tumor cancer cells tumor targeting gastrointestinal oncology cancer treatment molecular biology leukemia radiation oncology therapeutic targets clinical research gene expression dna repair medicinal research cancer genomics cancer care molecular cancer cancer genetics oncogenes molecular cell biology cytogenetics anti-cancer agents enhanced phosphorylation clinical trials cancer discovery enzyme inhibition pharmacotherapy cell cycle drug targeting potential therapeutic target gene expression signatures phase ii trial leukemia cells desmoid tumor genome biology gastrointestinal surgery clinical investigation cellular therapy vascular biology surgical pathology medical genetics cancer management gastrointestinal pharmacology treatment effects clinical evidence hematological malignancies host specificity tumor suppressors specific resistance drug targets therapeutic imaging clinical radiation oncology radiation therapy cell regulation gene regulation therapeutic efficacy apoptosis case series cellular biology cell growth cell proliferation tissue development oncogenic kit-containing exosomes frequent mutational inactivation lethal effect dna double-strand breaks neoadjuvant imatinib mesylate deep fibromatosis genomic profiles young adult population

Notable Scholarly Works

Notable Federal Grants

Collaborators

Supplementary Table S1 From Sar-096: Phase II Clinical Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (Ddl) and Leiomyosarcoma (Lms). (2024)

Data From Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data. (2023)

Michael F. OchsLori RinkChi TarnSarah MburuTakahiro TaguchiBurton EisenbergAndrew K. Godwin

signaling pathwaysepigenomicspharmacologytreatment-induced changescancer biologycancer researchcell signalingtranscriptomic databiostatisticsdata sciencegastrointestinal stromal tumorssignal transductionpathway analysis

Supplementary Figure Legend From Combination of Imatinib Mesylate and Akt Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor. (2023)

Phillip ZookHarsh B. PathakMartin G. BelinskyLawrence GerszKarthik DevarajanYan ZhouAndrew K. GodwinMargaret von MehrenLori Rink

pharmacologysynergistic effectsakt inhibitorgastrointestinal stromal tumorimatinib mesylatepreclinical study

Supplementary File 2- Preprocessed Cell Line Data From Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data. (2023)

Michael F. OchsLori RinkChi TarnSarah MburuTakahiro TaguchiBurton EisenbergAndrew K. Godwin

signaling pathwaystranscriptomics technologypharmacologytreatment-induced changescancer researchcell signalingbiomedical data analysiscell line datatranscriptomic datadata sciencegastrointestinal stromal tumorscancer biologypathway analysistumor biologybioinformaticscell biology

Supplementary File 5- Transcription P Values for All Cell Line Analysis From Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data. (2023)

Michael F. OchsLori RinkChi TarnSarah MburuTakahiro TaguchiBurton EisenbergAndrew K. Godwin

signaling pathwaystranscriptomics technologycell line analysistreatment-induced changescell signalingtranscriptomic datamolecular biologyoncologygastrointestinal stromal tumorscancer biologycell biology

Combined Inhibition of Akt and Kit Restores Expression of Programmed Cell Death 4 (Pdcd4) in Gastrointestinal Stromal Tumor. Cancers (2021)

Outcomes in the Dedifferentiated Liposarcoma Cohort of Sar-096, a Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (Ddl), and Leiomyosarcoma (Lms).. Journal of Clinical Oncology (2021)

Identification of Wee1 as a Target in Combination With Avapritinib for Gastrointestinal Stromal Tumor Treatment. JCI Insight (2020)

Shuai YeDinara SharipovaMarya KozinovaLilli KlugJimson D’SouzaMartin G. BelinskyKatherine J. JohnsonMargret B. EinarsonKarthik DevarajanYan ZhouSamuel LitwinMichael C. HeinrichRonald DeMatteoMargaret von MehrenJames S. DuncanLori Rink

immunologytumor targetingpharmacologypharmacotherapycancer immunotherapytherapeutic targetsanti-cancer agentsdrug targetingdrug targets

Identification of Wee1 as Target in Combination With Avapritinib for Gastrointestinal Stromal Tumor. JCI Insight (2020)

Identification of Wee1 as Target in Combination With Avapritinib for the Treatment of Gastrointestinal Stromal Tumor. bioRxiv (Cold Spring Harbor Laboratory) (2020)

tumor targetingpharmacologyantiviral drugspharmacotherapycancer immunotherapytherapeutic targetsanti-cancer agentsgastrointestinal stromal tumordrug targetingantiviral therapy

1
2
3
4
5
10 / page

Lori Rink

Associate Professor

Drexel University

Affiliations

College of Medicine

Biochemistry & Molecular Biology

Lori Rink is currently serving as a Biochemistry & Molecular Biology Associate Professor at Drexel University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Lori Rink

Drexel University

Associate Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Supplementary Table S1 From Sar-096: Phase II Clinical Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (Ddl) and Leiomyosarcoma (Lms). (2024)

Data From Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data. (2023)

Michael F. OchsLori RinkChi TarnSarah MburuTakahiro TaguchiBurton EisenbergAndrew K. Godwin

Supplementary Figure Legend From Combination of Imatinib Mesylate and Akt Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor. (2023)

Phillip ZookHarsh B. PathakMartin G. BelinskyLawrence GerszKarthik DevarajanYan ZhouAndrew K. GodwinMargaret von MehrenLori Rink

pharmacologysynergistic effectsakt inhibitorgastrointestinal stromal tumorimatinib mesylatepreclinical study

Supplementary File 2- Preprocessed Cell Line Data From Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data. (2023)

Michael F. OchsLori RinkChi TarnSarah MburuTakahiro TaguchiBurton EisenbergAndrew K. Godwin

Combined Inhibition of Akt and Kit Restores Expression of Programmed Cell Death 4 (Pdcd4) in Gastrointestinal Stromal Tumor. Cancers (2021)

Identification of Wee1 as a Target in Combination With Avapritinib for Gastrointestinal Stromal Tumor Treatment. JCI Insight (2020)

immunologytumor targetingpharmacologypharmacotherapycancer immunotherapytherapeutic targetsanti-cancer agentsdrug targetingdrug targets

Identification of Wee1 as Target in Combination With Avapritinib for Gastrointestinal Stromal Tumor. JCI Insight (2020)

Identification of Wee1 as Target in Combination With Avapritinib for the Treatment of Gastrointestinal Stromal Tumor. bioRxiv (Cold Spring Harbor Laboratory) (2020)

tumor targetingpharmacologyantiviral drugspharmacotherapycancer immunotherapytherapeutic targetsanti-cancer agentsgastrointestinal stromal tumordrug targetingantiviral therapy

1
2
3
4
5
10 / page

Similar Faculty Members

Pau Castel

Institution

New York University

oncogene

tumor biology

Donald J. Vander Griend

Institution

University of Illinois Chicago

oncogene

benign prostatic hyperplasia

Lyudmila Bazhenova

Institution

University of California, San Diego

bronchial neoplasm

molecular tumor board

Alana Welm

Institution

University of Utah

breast oncology

cancer biology

Jen Yeh

Institution

University of North Carolina at Chapel Hill

pathology

molecular cancer

Thomas Graeber

Institution

University of California, Los Angeles

cancer research

molecular diagnostics

Sarah Goldberg

Institution

Yale University

brain tumor research

bronchial neoplasm

Wei Zhou

Institution

Emory University

cancer genetics

oncogene

Ravi K. Amaravadi

Institution

University of Pennsylvania

oncology

cancer research

Chandra Belani

Institution

Pennsylvania State University

thoracic cancer team

clinical proteomics

Similar Faculty Members

Pau Castel

Institution

New York University

oncogene

tumor biology

Donald J. Vander Griend

Institution

University of Illinois Chicago

oncogene

benign prostatic hyperplasia

Lyudmila Bazhenova

Institution

University of California, San Diego

bronchial neoplasm

molecular tumor board

Alana Welm

Institution

University of Utah

breast oncology

cancer biology

Jen Yeh

Institution

University of North Carolina at Chapel Hill

pathology

molecular cancer

Thomas Graeber

Institution

University of California, Los Angeles

cancer research

molecular diagnostics

Sarah Goldberg

Institution

Yale University

brain tumor research

bronchial neoplasm

Wei Zhou

Institution

Emory University

cancer genetics

oncogene

Ravi K. Amaravadi

Institution

University of Pennsylvania

oncology

cancer research

Chandra Belani

Institution

Pennsylvania State University

thoracic cancer team

clinical proteomics